These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 32338224)

  • 1. Focus on Receptors for Coronaviruses with Special Reference to Angiotensin- Converting Enzyme 2 as a Potential Drug Target - A Perspective.
    Magrone T; Magrone M; Jirillo E
    Endocr Metab Immune Disord Drug Targets; 2020; 20(6):807-811. PubMed ID: 32338224
    [No Abstract]   [Full Text] [Related]  

  • 2. [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
    Kreutz R; Abd El-Hady Algharably E; Ganten D; Messerli F
    Pneumologie; 2020 Sep; 74(9):611-614. PubMed ID: 32916743
    [No Abstract]   [Full Text] [Related]  

  • 3. Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
    Huang Y; Xie C; Chen X; Hong Q; Huang H
    Pharmacol Res; 2020 Sep; 159():104959. PubMed ID: 32505834
    [No Abstract]   [Full Text] [Related]  

  • 4. ACE2 as a Potential Target for Management of Novel Coronavirus (nCoV- 2019).
    Foroozanfar E; Forouzanfar M; Farkhondeh T; Samarghandian S; Forouzanfar F
    Curr Drug Discov Technol; 2021; 18(6):e130921189567. PubMed ID: 33371835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
    Kreutz R; Abd El-Hady Algharably E; Ganten D; Messerli F
    Dtsch Med Wochenschr; 2020 May; 145(10):682-686. PubMed ID: 32323279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
    Shukla AK; Banerjee M
    High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.
    Malek Mahdavi A
    Rev Med Virol; 2020 Sep; 30(5):e2119. PubMed ID: 32584474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-converting enzyme as a new immunologic target for the new SARS-CoV-2.
    Hallaj S; Ghorbani A; Mousavi-Aghdas SA; Mirza-Aghazadeh-Attari M; Sevbitov A; Hashemi V; Hallaj T; Jadidi-Niaragh F
    Immunol Cell Biol; 2021 Feb; 99(2):192-205. PubMed ID: 32864784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apelin-potential therapy for COVID-19?
    Saeedi Saravi SS; Beer JH
    J Mol Cell Cardiol; 2020 Aug; 145():84-87. PubMed ID: 32562701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk and prognosis of COVID-19 in patients treated with renin-angiotensin-aldosterone inhibitors.
    Vistisen ST; Bodilsen J; Scheeren TWL; Simonsen U
    Eur J Anaesthesiol; 2020 Sep; 37(9):739-742. PubMed ID: 32769503
    [No Abstract]   [Full Text] [Related]  

  • 11. Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis.
    Greco A; Buccheri S; D'Arrigo P; Calderone D; Agnello F; Monte M; Milluzzo RP; Franchina AG; Ingala S; Capodanno D
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):335-337. PubMed ID: 32671399
    [No Abstract]   [Full Text] [Related]  

  • 12. This scientist hopes to test coronavirus drugs on animals in locked-down Wuhan.
    Cyranoski D
    Nature; 2020 Jan; 577(7792):607. PubMed ID: 31992886
    [No Abstract]   [Full Text] [Related]  

  • 13. Drugs and the renin-angiotensin system in covid-19.
    Aronson JK; Ferner RE
    BMJ; 2020 Apr; 369():m1313. PubMed ID: 32241880
    [No Abstract]   [Full Text] [Related]  

  • 14. RAAS blockers in hypertension posing a higher risk toward the COVID-19.
    Singh Y; Gupta G; Satija S; Negi P; Chellappan DK; Dua K
    Dermatol Ther; 2020 Jul; 33(4):e13501. PubMed ID: 32359088
    [No Abstract]   [Full Text] [Related]  

  • 15. Angiotensin-converting enzyme 2 and kidney diseases in the era of coronavirus disease 2019.
    Suh SH; Ma SK; Kim SW; Bae EH
    Korean J Intern Med; 2021 Mar; 36(2):247-262. PubMed ID: 33617712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two hits to the renin-angiotensin system may play a key role in severe COVID-19.
    Tseng YH; Yang RC; Lu TS
    Kaohsiung J Med Sci; 2020 Jun; 36(6):389-392. PubMed ID: 32492292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Renin-angiotensin-aldosterone blockers and Covic-19 infection : friends or enemies ?].
    Pechère-Bertschi A; Ponte B; Wuerzner G
    Rev Med Suisse; 2020 May; 16(693):1003-1007. PubMed ID: 32401442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [COVID-19 and its relationship with hypertension and cardiovascular disease].
    Salazar M; Barochiner J; Espeche W; Ennis I
    Hipertens Riesgo Vasc; 2020; 37(4):176-180. PubMed ID: 32591283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
    Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
    Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery.
    Lores E; Wysocki J; Batlle D
    Clin Sci (Lond); 2020 Nov; 134(21):2791-2805. PubMed ID: 33135725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.